Neuroscience and Behavioral Physiology

, Volume 10, Issue 6, pp 476–480 | Cite as

Use of blockers and stimulators of prolactin secretion in persistent lactorrhea-amenorrhea syndrome

  • N. T. Starkova
  • G. A. Mel'nichenko
Article
Received:
  • 14 Downloads

Conclusions

  1. 1.

    Rifathyroin — a domestic preparation of thyroliberin — is a powerful stimulator of prolactin secretion in healthy women.

     
  2. 2.

    In patients with the syndrome of persistent lactorrhea-amenorrhea the initial level of prolactin is considerably increased, however, prolactin secretion is decreased or absent when rifathyroin is administered.

     
  3. 3.

    In patients with a combination of primary hypothyroidism and lactorrhea-amenorrhea a moderate increase is observed in the initial level of prolactin, but an excessive increase in the secretion of the hormone occurs in response to the administration of rifathyroin.

     
  4. 4.

    In selecting a method of treatment for patients with the syndrome of persistent lactorrhea-amenorrhea without clinical or roentge nological signs of an adenoma of the hypophysis it is preferable to prescribe clomiphene or L-dopa, since these substances promote a decrease in the level of prolactin in the blood and restoration of a diphasic menstrual cycle, whereas against the background of treatment with estrogens prolactin secretion intensifies.

     

Keywords

Estrogen Adenoma Prolactin Hypothyroidism Menstrual Cycle 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literature cited

  1. 1.
    A. H. Tashjian, N. Y. Barowsky, and D. K. Yensen, Biochem. Biophys. Res. Commun.,43, 516–524 (1971).PubMedGoogle Scholar
  2. 2.
    C. J. Bowers, H. G. Friesen, and K. Folkers, ibid.,51, 512–531 (1973).PubMedGoogle Scholar
  3. 3.
    C. I. Nicoll and J. Meites, Endocrinology,70, 272–274 (1962).Google Scholar
  4. 4.
    G. L. Noel, H. K. Suh, and A. G. Frantz, J. Clin. Endocr.,36, 1255–1258 (1973).PubMedGoogle Scholar
  5. 5.
    R. M. MacLeod and Y. E. Lehmeyer, Endocrinology,94, 1077–1085 (1974).PubMedGoogle Scholar
  6. 6.
    K. Seki, M. Seki, T. Okumura et al., Am. J. Obstet. Gynec.,124, 125–128 (1976).PubMedGoogle Scholar
  7. 7.
    M. Otsuki, M. Tateiwa, and S. Baba, Endocr. Jpn.,20, 149–155 (1973).Google Scholar
  8. 8.
    D. F. Archer, H. R. Nankin, P. F. Galor, et al., Am. J. Obstet. Gynec.,119, 466–472 (1974).PubMedGoogle Scholar
  9. 9.
    E. del Poso, L. Varga, J. Wyus, et al., J. Clin. Endocr.,39, 19–26 (1974).Google Scholar
  10. 10.
    J. E. Tyson, B. Andreason, J. Huth, et al., Obstet. Gynec.,46, 1–11 (1975).PubMedGoogle Scholar
  11. 11.
    E. Hirvonen, T. Ramia, M. Seppala, J. Clin. Endocr.,42, 1024–1030 (1976).PubMedGoogle Scholar
  12. 12.
    L. Yamaji, Metabolism.,23, 745–751 (1974).PubMedGoogle Scholar
  13. 13.
    A. Munki, G. Schevinn, J. Koberling, et al., Act Endocr. (KBh.),184, 107–110 (1974).Google Scholar
  14. 14.
    R. H. Williams (editor), Textbook of Endocrinology, Philadelphia (1974).Google Scholar
  15. 15.
    S. N. Kheifets, Akush. Gin., No. 3, 47–50 (1975).Google Scholar
  16. 16.
    R. W. Turkington, J. Clin. Endocr.,34, 306–311 (1972).PubMedGoogle Scholar
  17. 17.
    A. Zarate, E. S. Canales, J. S. Jacobs, et al., Fertil. Steril.,24, 340–344 (1973).PubMedGoogle Scholar
  18. 18.
    G. A. Smyth and L. Lasarus, Endocrinology,93, 147–151 (1973).PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1981

Authors and Affiliations

  • N. T. Starkova
    • 1
  • G. A. Mel'nichenko
    • 1
  1. 1.Therapeutic Division, Institute of Experimental Endocrinology and Hormone ChemistryAcademy of Medical Sciences of the USSRMoscow

Personalised recommendations